Ginkgo Bioworks Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

• Ginkgo Bioworks Holdings Inc DNA.N reported a quarterly adjusted loss of $1.10​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-2.80. The mean expectation of three analysts for the quarter was for a loss of $1.57 per share. Wall Street expected results to range from $-1.77 to $-1.44 per share.

• Revenue fell 11.7% to $49.60 million from a year ago; analysts expected $41.61 million.

• Ginkgo Bioworks Holdings Inc's reported EPS for the quarter was a loss of $1.10​.

• The company reported a quarterly loss of $60.3 million.

• Ginkgo Bioworks Holdings Inc shares had risen by 24.1% this quarter and gained 42.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 5.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "sell" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and 3 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Ginkgo Bioworks Holdings Inc is $8.00, about 68.3% below its last closing price of $13.46

This summary was machine generated from LSEG data August 8 at 04:53 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)